321 related articles for article (PubMed ID: 29887244)
1. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
Sakashita S; Shiba-Ishii A; Murata Y; Sekimoto R; Minami Y; Sato Y; Noguchi M
Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
[TBL] [Abstract][Full Text] [Related]
2. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
4. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
[TBL] [Abstract][Full Text] [Related]
5. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
[TBL] [Abstract][Full Text] [Related]
6. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
7. EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.
Lavdovskaia ED; Iyevleva AG; Sokolenko AP; Mitiushkina NV; Preobrazhenskaya EV; Tiurin VI; Ivantsov AO; Bizin IV; Stelmakh LV; Moiseyenko FV; Karaseva NA; Orlov SV; Moiseyenko VM; Korzhenevskaya MA; Zaitsev IA; Kozak AR; Chistyakov IV; Akopov AL; Volkov NM; Togo AV; Imyanitov EN
Oncol Res Treat; 2018; 41(10):634-642. PubMed ID: 30145586
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.
Li C; Liu H; Zhang B; Gong L; Su Y; Zhang Z; Wang C
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1079-1086. PubMed ID: 29616327
[TBL] [Abstract][Full Text] [Related]
9. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
[TBL] [Abstract][Full Text] [Related]
10. [Epidermal growth factor receptor (EGFR) mutation status before and after acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma].
Ye SB; Li R; Shi SS
Zhonghua Bing Li Xue Za Zhi; 2017 Feb; 46(2):98-101. PubMed ID: 28173668
[No Abstract] [Full Text] [Related]
11. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
Huang YH; Hsu KH; Tseng JS; Chen KC; Hsu CH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
Cancer Res Treat; 2018 Oct; 50(4):1294-1303. PubMed ID: 29334606
[TBL] [Abstract][Full Text] [Related]
12. An Autopsy Case of Two Distinct, Acquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung Adenocarcinoma: Small Cell Carcinoma Transformation and Epidermal Growth Factor Receptor T790M Mutation.
Furugen M; Uechi K; Hirai J; Aoyama H; Saio M; Yoshimi N; Kinjo T; Miyagi K; Haranaga S; Higa F; Tateyama M; Fujita J
Intern Med; 2015; 54(19):2491-6. PubMed ID: 26424310
[TBL] [Abstract][Full Text] [Related]
13. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
[TBL] [Abstract][Full Text] [Related]
14. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma].
Du J; Wang Z; Yang L; Di J; Zhang JG; Wang TY; Liu DG
Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):35-39. PubMed ID: 29365415
[No Abstract] [Full Text] [Related]
16. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
17. Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas.
Cai YR; Dong YJ; Wu HB; Liu ZC; Zhou LJ; Su D; Chen XJ; Zhang L; Zhao YL
Sci Rep; 2016 Apr; 6():23755. PubMed ID: 27046167
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
19. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
20. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
Sueoka-Aragane N; Katakami N; Satouchi M; Yokota S; Aoe K; Iwanaga K; Otsuka K; Morita S; Kimura S; Negoro S;
Cancer Sci; 2016 Feb; 107(2):162-7. PubMed ID: 26577492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
